Bleeding Disorders
From the Journals
Improved treatments emerge for hemophilia patients with high-titer inhibitors
Use of traditional bypassing agents is expected to decrease over time as improved therapeutics are developed.
From the Journals
Cardiovascular disease risk unchanged in men with hemophilia A
Concerns about an elevated cardiovascular disease risk in hemophilia A patients may be unfounded, a new study suggests.
News
Canada approves Jivi for hemophilia A
Health Canada has approved Jivi® (antihemophilic factor [recombinant, B-domain deleted, PEGylated]) for use in patients with hemophilia A. Jivi (...
From the Journals
Genetic variants linked to warfarin-related bleeding in patients of African descent
Four SNPs associated with increased bleeding risk were identified in African American patients on warfarin, including one seen in one-third of...
News
Inhibitor receives orphan designation for ITP
The U.S.
News
CHMP recommends change for eptacog alfa
The European Medicine’s Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of the marketing...
News
FDA approves DNA-based blood type test
This is the first molecular-based test for red blood cell types to report genotypes in its results.
From the Journals
Genomic profiling predicts outcomes in patients with MPN
In blood cancers, there is a shift away from clinical and morphologic classification and toward genomic classification.
News
Variant not associated with CLL, AIHA, or ITP in certain patients
DUBROVNIK, CROATIA—New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or...
News
Emicizumab now also approved for hemophilia A without inhibitors
The U.S.
News
FDA approves emicizumab for hemophilia A without inhibitors
Emicizumab-kxwh (Hemlibra) is now approved to treat all age groups with hemophilia A, with or without factor VIII inhibitors.